Clinical trials: Upper Limb
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
- Trial name
- NCT04052997
- Testing
- Camidanlumab Tesirine
- Where
- 73 sites in United States, Belgium and 9 more
- Volunteers
- 117 people
- Sponsor
- ADC Therapeutics S.A.
Peripheral Vascular Disease
Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
To determine the safety and efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in subjects with atherosclerotic de novo or restenotic lesions in the native common iliac artery and/or native external iliac…
- Trial name
- MOBILITY OE (NCT01396525)
- Testing
- Omnilink Elite™ Peripheral Balloon-Expandable Stent System
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Abbott Medical Devices
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study was designed to evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with recurrent low-grade intermediate-risk…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- UTOPIA (NCT06331299)
- Testing
- UGN-103
- Where
- 48 sites in United States, Bulgaria and 5 more
- Volunteers
- 99 people
- Sponsor
- UroGen Pharma Ltd.
Well-differentiated Pancreatic Neuroendocrine Tumor
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
- Trial name
- NCT01525550
- Testing
- sunitinib
- Where
- 26 sites in United States, Australia and 13 more
- Volunteers
- 106 people
- Sponsor
- Pfizer
Coronary Artery Disease
Observational Registry Study: FIREHAWK DES for Treating Coronary Artery Disease (CAD)
The study aims to further assess the safety, efficacy and the performance of its delivery system of FIREHAWK rapamycin-eluting stent up to five years.
- Trial name
- NCT01412164
- Testing
- FIREHAWK biodegradable polymer rapamycin-eluting stent
- Where
- China
- Volunteers
- 730 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Paroxysmal Nocturnal Hemoglobinuria
Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
The primary purpose of this study is to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab in participants who are prescribed and are receiving a higher than approved dose of eculizumab to treat…
- Trial name
- NCT04320602
- Testing
- Eculizumab, Ravulizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acute Pain
A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy
This is a Phase 2 randomized, double-blind, placebo-controlled, 3-arm, parallel design study to evaluate the efficacy and safety of VX-150 in treating acute pain following bunionectomy.
- Trial name
- NCT03206749
- Testing
- VX-150, HB/APAP
- Where
- 4 sites in United States
- Volunteers
- 243 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Advanced Solid Tumor
QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval as well as through a…
- Trial name
- NCT01106248
- Testing
- Eribulin Mesylate
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- Eisai Limited
Leukaemia, Lymphoblastic
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
This study is an open-label, single arm, phase II study of chlorambucil in subjects with previously untreated CLL. The primary objective is to evaluate the response to chlorambucil in Japanese subjects with previously untreated…
- Trial name
- NCT01808326
- Testing
- chlorambucil, tablets
- Where
- 6 sites in Japan
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
MGMT-unmethylated Glioblastoma (GBM), GBM
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
This is a single arm, open-label, phase II trial of nivolumab, ipilimumab and short-course radiation therapy in adult patients with newly diagnosed, MGMT unmethylated GBM with the primary objective of determining the overall…
- Trial name
- NCT03367715
- Testing
- Nivolumab, Ipilimumab, Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NYU Langone Health
Human Influenza
A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.
The present study is designed to evaluate the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years.
- Trial name
- NCT02427750
- Testing
- Aggripal®
- Where
- Brazil
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Coronary Artery Disease, Myocardial Infarction
Disrupt CAD III With the Shockwave Coronary IVL System
The study design is a prospective, multicenter, single-arm, global IDE study to evaluate the safety and effectiveness of the Shockwave Medical Coronary Intravascular Lithotripsy (IVL) System in de novo, calcified, stenotic…
- Trial name
- NCT03595176
- Testing
- Lithotripsy
- Where
- 48 sites in United States, France and 2 more
- Volunteers
- 431 people
- Sponsor
- Shockwave Medical, Inc.
Thalassemia Major
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Patients with severe thalassemia (thalassemia major) present with severe anemia that required life-long transfusion therapy, spleen enlargement that led to increased transfusion requirement, and other serious complications as…
- Trial name
- NCT02049450
- Testing
- ruxolitinib
- Where
- 7 sites in Greece, Italy and 3 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density
- Trial name
- NCT00325468
- Testing
- AMG 162
- Volunteers
- 200 people
- Sponsor
- Amgen
Recurrent Glioblastoma
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
This study of DSF-Cu in combination with TMZ for recurrent GBM will evaluate the antitumor effect in patients who have recurrent GBM.
- Trial name
- NCT03034135
- Testing
- Disulfiram/Copper, Temozolomide (TMZ)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cantex Pharmaceuticals
Prostate Cancer
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
The aim of the study is to determine if triptorelin formulated for use every 6 months (given twice during the study) is effective and safe for when given by injection under the skin for the treatment of adult males with cancer in…
- Trial name
- TriptoSwitch (NCT05458856)
- Testing
- Triptorelin embonate 22.5 mg
- Where
- 39 sites in Belgium, Czechia and 5 more
- Volunteers
- 147 people
- Sponsor
- Ipsen
Spasticity
MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity
This study is a randomized, double blind, multi-center, active drug controlled, phase III clinical trial to compare the efficacy and safety of MEDITOXIN® versus BOTOX® in treatment of post stroke upper limb(wrist, finger, thumb)…
- Trial name
- NCT01313767
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Medy-Tox
Metastatic Colorectal Cancer
BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC
This is a single arm Phase Ib/II, open label, safety, pharmacokinetic, pharmacodynamics and efficacy study of ONC201 in combination with Opdivo (Nivolumab) in adult patients with metastatic colorectal cancer, for whom no standard…
- Trial name
- 379 (NCT03791398)
- Testing
- Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201 375mg
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Brown University
Coronary Artery Disease, General Anesthetic Drug Allergy
Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
Xenon is a gaseous anaesthetic agent registered in several European countries. It has been administered safely during cardiac surgery in pilot studies.
- Conditions
- Coronary Artery Disease, General Anesthetic Drug Allergy, Coronary Artery Bypass Graft Surgery
- Trial name
- NCT01294163
- Testing
- Xenon, Sevoflurane, Propofol
- Where
- 17 sites in France, Germany and 2 more
- Volunteers
- 509 people
- Sponsor
- Air Liquide Santé International
Breast Cancer
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib and aromatase inhibitor letrozole) as a first or…
- Trial name
- NCT03054363
- Testing
- Tucatinib in Combination with Palbociclib and Letrozole
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.